A new federal regulation extends the $35 monthly insulin price cap to all insurance plans, including employer-sponsored coverage, effective July 1, 2026. Previously, the cap only applied to Medicare.
Impact
- 8.4 million insulin users will see savings
- Average savings: $150/month for uninsured patients
- Applies to all insulin types: rapid, long-acting, mixed
- Covers both pen and vial formulations
The regulation also includes provisions for insulin pump supplies, capping out-of-pocket costs at $50/month. Diabetes advocacy groups call this the most significant drug pricing reform since Medicare Part D.
